DZ Bank AG reissued their buy rating on shares of Bayer AG (FRA:BAYN) in a research report sent to investors on Tuesday.

A number of other research analysts have also recently issued reports on the stock. J P Morgan Chase & Co reaffirmed a buy rating on shares of Bayer AG in a report on Wednesday, September 13th. Goldman Sachs Group, Inc. (The) set a €125.00 ($145.35) target price on shares of Bayer AG and gave the company a buy rating in a report on Monday, July 24th. Commerzbank Ag set a €124.00 ($144.19) target price on shares of Bayer AG and gave the company a buy rating in a report on Monday, August 28th. Sanford C. Bernstein set a €126.00 ($146.51) target price on shares of Bayer AG and gave the company a buy rating in a report on Tuesday, September 5th. Finally, Nord/LB set a €106.00 ($123.26) target price on shares of Bayer AG and gave the company a neutral rating in a report on Friday, July 28th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and fourteen have given a buy rating to the company. Bayer AG presently has an average rating of Buy and a consensus price target of €122.43 ($142.36).

Bayer AG (FRA:BAYN) opened at €107.55 ($125.06) on Tuesday. Bayer AG has a 1-year low of €86.06 ($100.07) and a 1-year high of €123.82 ($143.98).

COPYRIGHT VIOLATION NOTICE: “Bayer AG’s (BAYN) Buy Rating Reiterated at DZ Bank AG” was published by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/bayer-ags-bayn-buy-rating-reiterated-at-dz-bank-ag/1711046.html.

Bayer AG Company Profile

Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and womenÂ’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Analyst Recommendations for Bayer AG (FRA:BAYN)

Receive News & Ratings for Bayer AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer AG and related companies with Analyst Ratings Network's FREE daily email newsletter.